The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives
Abstract
The advent of SELEX (systematic evolution of ligands by exponential enrichment) technology has shown the ability to evolve artificial ligands with affinity and specificity able to meet growing clinical demand for probes that can, for example, distinguish between the target leukemia cells and other cancer cells within the matrix of heterogeneity, which characterizes cancer cells. Though antibodies are the conventional and ideal choice as a molecular recognition tool for many applications, aptamers complement the use of antibodies due to many unique advantages, such as small size, low cost, and facile chemical modification. This Minireview will focus on the novel applications of aptamers and SELEX, as well as opportunities to develop molecular tools able to meet future clinical needs in biomedicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Overview of the immune response
Chaplin, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.980 · Cited by 2,235
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Aptamers evolved from live cells as effective molecular probes for cancer study
Shangguan, D., Li, Y., Tang, Z., Cao, Z. C., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. J., & Tan, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602615103 · Cited by 1,516
Self-citationA DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
Li, S., Jiang, Q., Liu, S., Zhang, Y., Tian, Y., Song, C., Wang, J., Zou, Y., Anderson, G. J., Han, J.-Y., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4071 · Cited by 1,471
Self-citationSELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.06.001 · Cited by 1,430
Cited by
Analysis of therapeutic nucleic acids by capillary electrophoresis
Wei, B., Goyon, A., & Zhang, K. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.114928 · Cited by 50
Metadata
- Authors
- Li, L., Xu, S., Yan, H., Li, X., Yazd, H. S., Li, X., Huang, T., Cui, C., Jiang, J., & Tan, W.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2020-08-13
- Volume
- 60
- Issue
- 5
- Pages
- 2221-2231
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W3015973618
- Cited by
- 432
- References
- 105
- FWCI
- 14.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives. https://app.cochat.ai/papers/10.1002/anie.202003563
- The paper
- Li, L., Xu, S., Yan, H., Li, X., Yazd, H. S., Li, X., Huang, T., Cui, C., Jiang, J., & Tan, W. (2021). Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202003563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
